Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Candel Therapeutics Inc (CADL)

Candel Therapeutics Inc (CADL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 296,109
  • Shares Outstanding, K 50,103
  • Annual Sales, $ 0 K
  • Annual Income, $ -55,180 K
  • EBIT $ -34 M
  • EBITDA $ -33 M
  • 60-Month Beta -0.92
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.76

Options Overview Details

View History
  • Implied Volatility 108.11% ( -11.77%)
  • Historical Volatility 80.57%
  • IV Percentile 27%
  • IV Rank 20.89%
  • IV High 452.22% on 12/10/24
  • IV Low 17.26% on 08/09/24
  • Put/Call Vol Ratio 0.11
  • Today's Volume 588
  • Volume Avg (30-Day) 713
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 15,660
  • Open Int (30-Day) 16,132

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.17
  • Number of Estimates 1
  • High Estimate -0.17
  • Low Estimate -0.17
  • Prior Year -0.74
  • Growth Rate Est. (year over year) +77.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.34 +35.30%
on 05/08/25
5.93 -1.10%
on 05/20/25
+1.36 (+30.16%)
since 04/21/25
3-Month
4.25 +38.12%
on 04/09/25
12.02 -51.16%
on 02/24/25
-5.76 (-49.53%)
since 02/21/25
52-Week
3.79 +55.09%
on 11/15/24
14.60 -59.79%
on 12/11/24
-6.40 (-52.16%)
since 05/21/24

Most Recent Stories

More News
Best Momentum Stocks to Buy for May 19th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 19th:Candel Therapeutics, Inc. CADL: This clinical stage biopharmaceutical company has a Zacks...

MAG : 18.42 (+1.71%)
HMN : 43.96 (unch)
CADL : 5.87 (-0.68%)
New Strong Buy Stocks for May 19th

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Subsea 7 S.A. SUBCY: This company that delivers offshore projects and services for the energy sector has seen the Zacks Consensus...

BPOP : 105.15 (-0.13%)
KARO : 54.62 (-0.31%)
MAG : 18.42 (+1.71%)
CADL : 5.87 (-0.68%)
SUBCY : 16.2800 (+0.93%)
Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

CADL : 5.87 (-0.68%)
Candel Therapeutics to Present at Upcoming Investor Conferences

CADL : 5.87 (-0.68%)
Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

CADL : 5.87 (-0.68%)
Private Sector Steps Up in Cancer Research as Federal Support Wavers

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As the Trump administration signals potential cuts to the National Institutes of Health (NIH), questions...

ONCY : 0.4599 (+7.03%)
SMMT : 24.24 (-0.62%)
CADL : 5.87 (-0.68%)
IMTX : 5.39 (-0.19%)
EXEL : 44.00 (-0.81%)
ONC.TO : 0.60 (-7.69%)
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

CADL : 5.87 (-0.68%)
Candel’s Final Survival Data From Lung Cancer Drug Trial Lifts Stock After-Hours, Fuels Retail Optimism

The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years.

CADL : 5.87 (-0.68%)
VTI : 290.00 (-0.63%)
HDG : 49.44 (-0.02%)
IWM : 206.80 (-1.09%)
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

CADL : 5.87 (-0.68%)
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

CADL : 5.87 (-0.68%)

Business Summary

Candel Therapeutics Inc. is a late clinical stage biopharmaceutical company. It involved in developing novel oncolytic viral immunotherapies. The company's product pipeline includes CAN-2409 and CAN-3110. Candel Therapeutics Inc. is based in NEEDHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 6.47
2nd Resistance Point 6.20
1st Resistance Point 6.06
Last Price 5.87
1st Support Level 5.64
2nd Support Level 5.37
3rd Support Level 5.23

See More

52-Week High 14.60
Fibonacci 61.8% 10.47
Fibonacci 50% 9.19
Fibonacci 38.2% 7.92
Last Price 5.87
52-Week Low 3.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
OSZAR »